Effect of recombinant human erythropoietin in preterm infants

Twenty‐five premature infants (mean gestational age±SD, 31.4±1.9 weeks) were administered subcutaneously recombinant human erythropoietin (rHuEpo) at a dose of 300 u/kg of body weight three times a week beginning on the third day of life and continuing for 6 weeks. The controls (n=23) were premature...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of haematology 1999-08, Vol.63 (2), p.71-76
Hauptverfasser: Krallis, Nikolaos, Cholevas, Vasilis, Mavridis, Anestis, Georgiou, Ioannis, Bourantas, Konstantinos, Andronikou, Styliani
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Twenty‐five premature infants (mean gestational age±SD, 31.4±1.9 weeks) were administered subcutaneously recombinant human erythropoietin (rHuEpo) at a dose of 300 u/kg of body weight three times a week beginning on the third day of life and continuing for 6 weeks. The controls (n=23) were premature infants with a mean gestational age of 32.2±2.3 weeks who did not receive rHuEpo. Haematological indices, haemoglobin and serum phosphate (Pi), and red blood cell (RBC) phosphate metabolites (ATP, 2,3‐DPG, RBCPi) were tested monthly until the 6th month and thereafter at the 9th and 12th months of life. The level of serum soluble transferrin receptors (sTfR) correlated significantly with rHuEpo (p
ISSN:0902-4441
1600-0609
DOI:10.1111/j.1600-0609.1999.tb01119.x